164 related articles for article (PubMed ID: 28985927)
1. Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis.
Shammas RL; Cho EH; Glener AD; Poveromo LP; Mundy LR; Greenup RA; Blackwell KL; Hollenbeck ST
J Am Coll Surg; 2017 Dec; 225(6):731-739.e1. PubMed ID: 28985927
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data.
Ates O; Oksuzoglu OB; Aktas BY; Karadag I; Esen S; Karakaya S; Uncu D; Erol C; Gurbuz M; Yalcin B; Aksoy S
J BUON; 2021; 26(4):1398-1404. PubMed ID: 34564997
[TBL] [Abstract][Full Text] [Related]
3. Pertuzumab and trastuzumab: the rationale way to synergy.
Richard S; Selle F; Lotz JP; Khalil A; Gligorov J; Soares DG
An Acad Bras Cienc; 2016; 88 Suppl 1():565-77. PubMed ID: 27275646
[TBL] [Abstract][Full Text] [Related]
4. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
[TBL] [Abstract][Full Text] [Related]
5. Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.
Lee A; Jo S; Lee C; Shin HH; Kim TH; Ahn KJ; Park SK; Cho H; Yoon HK; Kim WG; Park J; Choi Y
Breast Cancer; 2019 Sep; 26(5):672-680. PubMed ID: 30927244
[TBL] [Abstract][Full Text] [Related]
6. Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.
Ajgal Z; de Percin S; Diéras V; Pierga JY; Campana F; Fourquet A; Kirova YM
Cancer Radiother; 2017 Apr; 21(2):114-118. PubMed ID: 28347625
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
Guardia C; Bianchini G; Arpí-LLucià O; Menendez S; Casadevall D; Galbardi B; Dugo M; Servitja S; Montero JC; Soria-Jiménez L; Sabbaghi M; Peña R; Madoz-Gúrpide J; Lloveras B; Lluch A; Eroles P; Arribas J; Pandiella A; Gianni L; Rojo F; Rovira A; Albanell J
Clin Cancer Res; 2021 Sep; 27(18):5096-5108. PubMed ID: 34385295
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns among elderly patients with stage IV breast cancer treated with HER-2-targeted therapy.
Lang K; Hao Y; Huang H; Lin I; Rogerio JW; Menzin J
J Comp Eff Res; 2014 Sep; 3(5):481-90. PubMed ID: 25350800
[TBL] [Abstract][Full Text] [Related]
10. What is the best time for 18F-FDG-PET evaluation in estrogen receptor-negative and HER2-positive breast cancer patients receiving neoadjuvant trastuzumab and pertuzumab?
Altundag K
J BUON; 2021; 26(4):1685. PubMed ID: 34565040
[No Abstract] [Full Text] [Related]
11. [HER2-positive breast cancer: standard and double targeted therapy].
Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy.
Chen TH; Zhang YC; Tan YT; An X; Xue C; Deng YF; Yang W; Yuan X; Shi YX
Oncotarget; 2017 Jan; 8(3):5219-5232. PubMed ID: 28029650
[TBL] [Abstract][Full Text] [Related]
13. Surgical Outcomes for Mastectomy Patients Receiving Neoadjuvant Chemotherapy: A Propensity-Matched Analysis.
Bowen ME; Mone MC; Buys SS; Sheng X; Nelson EW
Ann Surg; 2017 Mar; 265(3):448-456. PubMed ID: 27280515
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
Mayer EL; Gropper AB; Harris L; Gold JM; Parker L; Kuter I; Come S; Najita JS; Guo H; Winer EP; Burstein HJ
Clin Breast Cancer; 2015 Feb; 15(1):24-30. PubMed ID: 25205424
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer.
Dai WF; Beca JM; Nagamuthu C; Liu N; de Oliveira C; Earle CC; Trudeau M; Mercer RE; Chan KKW
JAMA Netw Open; 2022 Feb; 5(2):e2145460. PubMed ID: 35226087
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
Fasching PA; Hartkopf AD; Gass P; Häberle L; Akpolat-Basci L; Hein A; Volz B; Taran FA; Nabieva N; Pott B; Overkamp F; Einarson H; Hadji P; Tesch H; Ettl J; Lüftner D; Wallwiener M; Müller V; Janni W; Fehm TN; Schneeweiss A; Untch M; Pott D; Lux MP; Geyer T; Liedtke C; Seeger H; Wetzig S; Hartmann A; Schulz-Wendtland R; Belleville E; Wallwiener D; Beckmann MW; Brucker SY; Kolberg HC
Breast Cancer Res Treat; 2019 Jan; 173(2):319-328. PubMed ID: 30324275
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
18. Preference of trastuzumab emtansine as a second or third line treatment in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer refractory to trastuzumab and pertuzumab.
Altundag K
J BUON; 2021; 26(5):2206-2207. PubMed ID: 34761643
[No Abstract] [Full Text] [Related]
19. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
[TBL] [Abstract][Full Text] [Related]
20. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
